Mapi Research Trust
Mapi Research Trust is recorded as a service provider in 52 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 52 trials · Latest update first
HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.
Sponsor Chemo Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
BEACON2: A multi-arm multi-stage platform trial for relapsed neuroblastoma
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis
Sponsor Alexion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Sponsor Insmed Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A two-year, double-blind, randomized, multicenter, active-controlled Core Phase study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension Phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED)
Sponsor Pierre Fabre Medicament
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis
Sponsor Rein Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase. Name: SKYPS
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad)
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Mapi Research Trust?
The 2026-10-09 snapshot links Mapi Research Trust to 52 distinct CTIS trials. Recorded services include Clinical outcome assessments, Electronic data capture, COA licensing, L-PF questionnaire license, among 34 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Mapi Research Trust?
The most frequently recorded therapeutic areas are Immunology, Neurology, Respiratory, Rheumatology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Mapi Research Trust conducted?
The linked trials record locations in 25 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where Mapi Research Trust delivered services.
What can this page tell me about Mapi Research Trust's trial experience?
Browse 52 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Mapi Research Trust. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Mapi Research Trust